Grade III Astrocytic Tumor

A grade III astrocytic tumor is a fast-growing brain cancer that develops from star-shaped support cells called astrocytes. In modern classification, most adult grade III tumors in this family are called “astrocytoma, IDH-mutant, CNS WHO grade 3.” Under the microscope, the cells look very abnormal and divide actively (“anaplastic” with mitoses), but they do not show the dead tissue or abnormal new blood vessels that define grade 4 (glioblastoma). Today, diagnosis also includes molecular tests: most adult cases carry an IDH1/IDH2 mutation and often show ATRX loss and p53 overexpression; if a tumor with IDH mutation also has CDKN2A/B homozygous deletion, it is upgraded to grade 4 even if the slides look only grade 3. These biology rules help doctors name the tumor correctly and plan care. PMC+2AJNR+2

A grade III astrocytic tumor is a faster‑growing brain tumor that starts from star‑shaped brain cells called astrocytes. In today’s system, most tumors once called “anaplastic astrocytoma” are now named astrocytoma, IDH‑mutant, CNS WHO grade 3, because the tumor’s IDH gene change is used to define the disease and guide treatment. These tumors spread into nearby brain tissue (they are “diffuse”), so even with surgery, tiny cells often remain. Standard care usually includes maximal safe surgery, radiation, and temozolomide (TMZ) chemotherapy after radiation; this sequence improved survival in the landmark CATNON trial for IDH‑mutant disease. Your team also manages symptoms such as swelling, seizures, and fatigue. [1–5,8,17]

---

Other names

Doctors have used several names for this tumor over time. You may see anaplastic astrocytoma (WHO grade III) in older reports. In the current WHO system, the preferred name for most adult cases is astrocytoma, IDH-mutant, CNS WHO grade 3. “High-grade astrocytoma (grade 3)” is a plain-language label sometimes used in patient guides. These labels all describe the same clinical idea: a malignant, faster-growing astrocytic tumor that is not glioblastoma. PMC+1

---

Types

1. By modern biology (most important):
   • Adult-type, IDH-mutant astrocytoma, grade 3 (the main entity).
   • IDH-wildtype tumors with grade 3 histology are usually reclassified as glioblastoma (grade 4) if they show certain “molecular glioblastoma” features (e.g., TERT promoter mutation with EGFR amplification or +7/−10 chromosome pattern). This change prevents undertreatment. PMC

2. By location:
   The tumor can arise in the cerebral hemispheres (most common), but may also occur in deep gray nuclei, thalamus, cerebellum, or brainstem. Symptoms depend on where it grows and what functions that area controls. Cancer.gov

3. By historical microscopic patterns:
   Older terms like “fibrillary” or “gemistocytic” describe how cells look but are less important now than the IDH status and other markers, which drive naming and prognosis. PMC

---

Causes / Risk factors

Key idea: For most people, no single cause is found. A grade III astrocytoma usually starts because of random DNA changes in brain cells over time (often including an IDH mutation), not because of anything a person did. A few exposures and rare inherited syndromes increase risk. Where evidence is weak, that is noted. PMC

1. Natural, random DNA changes with age (sporadic mutation).
   Most tumors arise from chance genetic errors in dividing cells. In astrocytoma, the IDH mutation is a common first step in adults. PMC

2. Prior ionizing radiation to the head.
   Radiation given in childhood or young adulthood (for another disease) slightly raises later brain-tumor risk, including gliomas. This is the best-proven environmental risk. American Cancer Society

3. Li-Fraumeni syndrome (TP53).
   A rare inherited TP53 mutation raises risk for several cancers, including gliomas. American Cancer Society

4. Neurofibromatosis type 1 (NF1).
   NF1 increases risk of certain gliomas; while optic-pathway gliomas are typical, diffuse astrocytomas can also occur. American Cancer Society

5. Tuberous sclerosis complex (TSC1/TSC2).
   TSC predisposes to astrocytic tumors (classically subependymal giant cell astrocytoma). It illustrates how an inherited pathway error can drive astrocyte tumors. American Cancer Society

6. Turcot syndrome / Lynch spectrum (DNA mismatch-repair).
   Turcot (APC or MMR gene changes) is linked to brain tumors; in MMR-deficient families some gliomas occur. American Cancer Society

7. Von Hippel–Lindau (VHL) and other rare syndromes.
   VHL chiefly causes hemangioblastomas, but belongs to the small group of inherited disorders tied to CNS tumors; its inclusion shows the role of germline tumor-predisposition. American Cancer Society

8. Cowden / PTEN hamartoma tumor syndrome.
   A rarer inherited pathway problem that can increase risk for several tumors; occasional gliomas reported. American Cancer Society

9. Family history of brain tumors (without a named syndrome).
   A small proportion of gliomas cluster in families, suggesting shared genes or environment. American Cancer Society

10. Male sex (possible small excess for some gliomas).
    Some series show modest male predominance for diffuse gliomas overall, but data vary and this is not a strong or actionable factor. National Brain Tumor Society

11. High-dose occupational medical radiation (rare today).
    Historically linked to increased glioma risk; modern protections reduce exposure. American Cancer Society

12. IDH mutation biology itself.
    The IDH mutation rewires cell metabolism (2-HG production) and DNA methylation (G-CIMP), setting the stage for astrocytoma growth; it is a driver rather than a “cause” you can avoid. PMC

13. Cooperating tumor-suppressor changes (ATRX, TP53).
    Loss of ATRX and mutations in TP53 commonly partner with IDH mutations in astrocytomas, helping the tumor grow. PMC

14. CDKN2A/B deletion (progression driver).
    When this occurs in an IDH-mutant astrocytoma, the disease behaves more aggressively and is graded 4. PMC+1

15. Weakened immune system (limited link to glioma).
    Immunosuppression clearly increases lymphoma risk; any effect on astrocytoma risk is less certain and likely small. American Cancer Society

16. Cell phones and non-ionizing EMF (unproven).
    Large studies have not shown a consistent increase in glioma risk; evidence remains uncertain and guidelines do not treat this as causal. American Cancer Society

17. Head injury (unproven).
    Research has not shown a reliable, causal link between trauma and later astrocytoma. American Cancer Society

18. Lifestyle factors (tobacco, diet, etc., unproven).
    Unlike many cancers, typical lifestyle risks have no clear, strong link to glioma. American Cancer Society

19. Childhood factors (few proven risks).
    In children, very few risk factors for brain tumors are known; most cases happen without a clear cause. American Cancer Society

20. Prior cranial surgery or infections (no proven causal link).
    These are not established causes of astrocytoma; evaluation focuses on the tumor’s current biology. American Cancer Society

---

Symptoms

Important: Symptoms vary by size and location. Any new seizure, persistent morning headache with vomiting, rapidly worsening neurological problem, or behavior change should be assessed urgently. Cancer.gov

1. Headache that worsens over time, often worse in the morning, sometimes eased by vomiting. This pattern can reflect raised pressure inside the skull. Cancer.gov+2Mayo Clinic+2

2. Seizures (new-onset). Many astrocytomas first present with a seizure. Cancer.gov

3. Weakness or clumsiness of an arm or leg. Tumors in motor pathways cause focal weakness and poor coordination. Cancer.gov

4. Speech or language trouble. Lesions in the dominant hemisphere can cause word-finding or understanding problems. Cancer.gov

5. Changes in personality, mood, or judgment. Frontal lobe tumors may cause apathy, irritability, or poor decision-making. Cancer.gov

6. Memory and concentration problems. Slow processing or forgetfulness can develop. Mayo Clinic

7. Visual changes. Blurry or double vision, or loss of side vision, may occur from occipital/optic pathway involvement or raised pressure. Cancer.gov

8. Balance problems and falls. Cerebellar or sensory pathway involvement causes unsteady gait. National Brain Tumor Society

9. Nausea and vomiting not explained by stomach illness. Often goes with raised intracranial pressure. Cancer.gov

10. Sleepiness or reduced activity level. Increased pressure or diffuse brain dysfunction can cause somnolence. Cancer.gov

11. Numbness or tingling. Sensory pathway tumors cause altered feeling. National Brain Tumor Society

12. Hearing changes or ringing. Temporal lobe or brainstem involvement can affect hearing. Cancer.gov

13. Papilledema (optic-disc swelling) signs—transient visual dimming, pulsatile tinnitus. Found on eye exam when pressure is elevated. NCBI

14. Dizziness or vertigo. Especially with cerebellar or brainstem tumors. National Brain Tumor Society

15. Headache that worsens with cough, bending, or straining. This is a classic “pressure” clue. PMC

---

Diagnostic tests

Below are common tests grouped by Physical Exam, Manual Tests (bedside maneuvers), Laboratory & Pathology, Electrodiagnostic, and Imaging. Most patients will need MRI with contrast and tissue testing (biopsy or surgical specimen) including modern molecular markers. PMC

1. Full neurological examination (Physical Exam).
   The doctor checks mental status, cranial nerves, strength, sensation, coordination, reflexes, and gait to map deficits and localize the lesion. This baseline also helps track change over time. University of Rochester Medical Center

2. Fundoscopic (eye) examination for papilledema (Physical Exam).
   Looking at the optic nerves can show swelling from raised intracranial pressure, an urgent sign often seen in large or obstructive tumors. NCBI

3. Mental-status and cognitive screening (Physical Exam).
   Brief tools (e.g., attention, memory, language tasks) document thinking problems that tumors can cause and help plan rehab. University of Rochester Medical Center

4. Cranial-nerve examination (Physical Exam).
   Tests of pupils, eye movements, facial muscles, hearing, palate, and tongue can localize tumor effects in the skull base or brainstem. NCBI

5. Confrontation visual-field testing (Manual test).
   A quick bedside check can detect blind spots or side-vision loss from occipital or optic-pathway involvement or from raised pressure. NCBI

6. Snellen visual-acuity test (Manual test).
   Simple chart testing documents blurring from tumor-related visual pathway problems or papilledema, and guides referrals. NCBI

7. Romberg test (Manual test).
   Standing with feet together and eyes closed screens for sensory ataxia and midline cerebellar issues that some tumors can cause. NCBI

8. Pronator-drift test (Manual test).
   Arms outstretched, palms up; downward drift suggests a corticospinal pathway problem caused by a tumor in motor areas. NCBI+1

9. Finger-to-nose / heel-to-shin (Manual test).
   These coordination maneuvers expose cerebellar dysfunction from posterior fossa or hemispheric lesions. University of Rochester Medical Center

10. Basic blood tests (Lab).
    Blood counts and chemistry help assess overall health and prepare for surgery or treatment; they do not diagnose the tumor but are routine. NCBI

11. Surgical biopsy or resection with histology (Pathology).
    Tissue examination confirms an astrocytic tumor with anaplasia and mitoses and rules out other cancers. Histology alone is no longer enough—molecular tests must follow. PMC

12. IDH mutation testing (Pathology).
    Immunohistochemistry detects the common IDH1 R132H change; sequencing covers non-R132H IDH1 and IDH2. This defines the tumor family and strongly affects naming and prognosis. PMC+1

13. ATRX and p53 immunostaining (Pathology).
    ATRX loss and p53 overexpression support an astrocytoma (and help distinguish from oligodendroglioma, which keeps ATRX and has 1p/19q codeletion). PMC+1

14. 1p/19q codeletion testing (Pathology).
    FISH or sequencing proves or excludes oligodendroglioma (which must have IDH mutation and 1p/19q codeletion). A grade 3 tumor without this codeletion and with IDH mutation is called astrocytoma, IDH-mutant. PMC

15. MGMT promoter methylation (Pathology).
    This epigenetic marker is common in IDH-mutant gliomas and informs prognosis and response to alkylating chemotherapy; it does not change the grade. PMC

16. DNA methylation profiling (Pathology, when available).
    Genome-wide methylation classifiers can resolve ambiguous cases by matching tumor “methylation class,” improving diagnostic accuracy in difficult samples. PMC

17. Electroencephalogram—EEG (Electrodiagnostic).
    If seizures occur (common at diagnosis), EEG helps confirm and classify them and guides antiseizure treatment; continuous EEG is used when events are unclear. Medscape+1

18. Evoked potentials (Electrodiagnostic, selected cases).
    Visual or brainstem auditory evoked responses can objectify pathway function when exam is limited, though they are not routine for all patients. NCBI

19. MRI of the brain with and without gadolinium contrast (Imaging—cornerstone test).
    MRI shows the tumor, its borders, edema, and mass effect. Advanced sequences (diffusion, perfusion, spectroscopy, tractography, functional MRI) refine grading and surgical planning, and help separate tumor from treatment effects later. RSNA Publications+2PMC+2

20. Amino-acid PET (FET, MET, FDOPA) in selected centers (Imaging).
    PET can improve tumor delineation, detect active tumor beyond MRI enhancement, and assist radiotherapy planning or recurrence assessment, per EANO/RANO practice guidance. PMC+1

Non‑pharmacological treatments

1. Maximal safe surgical resection
   What it is: Brain surgery aims to remove as much tumor as safely possible, often using neuronavigation and intra‑operative monitoring. Purpose: Reduce tumor burden, relieve pressure, and obtain tissue for exact diagnosis. Mechanism: Lowering tumor volume improves the effect of radiation/chemo and is linked with longer survival; awake mapping in eloquent areas helps preserve speech or movement. [21,28–30]
2. Post‑operative focal radiation therapy (RT)
   What it is: External‑beam RT (about 54–60 Gy in daily small doses) to the tumor region after healing from surgery. Purpose: Kill remaining tumor cells and delay regrowth. Mechanism: DNA damage in dividing tumor cells; target volumes are planned per modern ESTRO‑EANO/ASTRO guidance for IDH‑mutant grade 3 glioma. [5,6,18,23]
3. Cognitive rehabilitation
   What it is: Structured training (neuropsychology sessions, computer‑based drills, compensatory strategies). Purpose: Improve attention, memory, executive skills affected by tumor and treatment. Mechanism: Repeated practice and strategy training drive neuroplasticity and help patients function better at home and work; systematic reviews show benefit though programs vary. [0,4,12]
4. Speech‑language therapy
   What it is: Therapy to improve speaking, understanding, reading, or swallowing. Purpose: Prevent or reduce communication problems, especially after surgery near language areas. Mechanism: Task‑specific practice and cueing use brain networks around the surgical cavity to compensate; awake mapping plus targeted rehab lowers long‑term language deficits. [29,30]
5. Physical therapy & supervised exercise
   What it is: Tailored aerobic and resistance training plus balance work. Purpose: Maintain strength, reduce fatigue, improve mood and daily function. Mechanism: Exercise improves cardiorespiratory fitness, reduces treatment side‑effects, and enhances quality of life across cancers; evidence in glioma is growing, with ASCO recommending exercise during active treatment. [22,23,35]
6. Occupational therapy (OT)
   What it is: Training for daily tasks (self‑care, home/work adaptations, energy conservation). Purpose: Keep independence and safety. Mechanism: Task analysis, assistive tools, and graded practice reduce disability from cognitive or motor deficits. [12,16]
7. Psychological support & psycho‑oncology
   What it is: Counseling, CBT, mindfulness, support groups. Purpose: Treat anxiety/depression, coping with uncertainty, caregiver strain. Mechanism: Evidence links structured psycho‑oncology to better mood and resilience; mindfulness can improve sleep and stress. [12,22,23]
8. Seizure safety education
   What it is: Advice on triggers, sleep, medication adherence, driving/workplace safety. Purpose: Lower risk of injury and improve control. Mechanism: Behavioral strategies complement AEDs; clinician guidance reflects neuro‑oncology consensus. [14,15,33]
9. Nutrition counseling
   What it is: Dietitian‑guided plan to meet protein/energy needs, manage steroid‑related sugar and salt, and address nausea/constipation. Purpose: Maintain weight and healing; avoid unsafe restrictions. Mechanism: Cancer nutrition guidance discourages routine “neutropenic” diets and focuses on balanced intake; monitor steroid‑induced hyperglycemia. [24,26,27,34]
10. Fatigue management & sleep hygiene
    What it is: Activity pacing, brief daytime activity, regular bedtime, light therapy if needed. Purpose: Reduce cancer‑related fatigue and daytime sleepiness. Mechanism: Sleep‑behavior changes and graded activity improve energy and cognition. [12,22,23]
11. Edema management without drugs (positioning, head‑of‑bed elevation, salt moderation)
    Purpose: Reduce headache and pressure symptoms when lowering steroid doses. Mechanism: Basic measures lessen intracranial pressure swings and fluid retention. [32,34]
12. Venous thromboembolism (VTE) prevention strategies
    What it is: Early mobilization, compression devices during/after surgery. Purpose: Lower blood‑clot risk common in brain tumor patients. Mechanism: Mechanical prophylaxis complements short courses of heparin when safe post‑op per oncology/surgery guidance. [25,31]
13. Vocational counseling
    What it is: Planning graded return to work or role changes. Purpose: Preserve income and purpose. Mechanism: Matching cognitive/physical capacity to tasks improves sustainability and mood. [12,16]
14. Caregiver training
    What it is: Teaching partners/family about cues, safety, and symptom monitoring. Purpose: Reduce caregiver burden and prevent crises. Mechanism: Early education improves adherence and lowers emergency visits. [12,16]
15. Palliative care (early integration)
    What it is: Symptom‑focused support alongside active treatment. Purpose: Better quality of life, decision support, and home‑based care planning. Mechanism: Early palliative care improves symptom control and reduces distress in neuro‑oncology. [12]
16. Mind‑body therapies (yoga, tai chi, guided imagery)
    Purpose: Reduce anxiety, fatigue, and sleep problems; complement exercise. Mechanism: Autonomic balance and mindfulness can ease stress; multi‑cancer evidence supports safety and benefit. [22,23]
17. Cognitive‑behavioral pain & headache strategies
    Purpose: Reduce pain, medication needs, and catastrophizing. Mechanism: Skills reshape pain perception and coping. [12]
18. Swallowing therapy & aspiration prevention
    Purpose: Keep nutrition safe if cranial nerves/cortex affected. Mechanism: Targeted exercises and diet texture changes reduce aspiration risk. [12]
19. Driving assessment & safety
    Purpose: Determine when driving is unsafe after seizures/surgery. Mechanism: Neurocognitive testing and local rules reduce harm. [14,33]
20. Clinical trial enrollment (non‑drug or device arms)
    Purpose: Access advanced imaging‑guided RT planning, rehab tech, or digital coaching. Mechanism: Research protocols may enhance outcomes while contributing knowledge. [18,23]

Drug treatments

1. Temozolomide (TMZ)
   Class: Oral alkylating agent. Dose/Time: Often 75 mg/m² daily during RT is not clearly beneficial for IDH‑mutant grade 3 per CATNON; the most evidence‑supported part is adjuvant TMZ 150–200 mg/m² daily on Days 1–5 every 28 days for 12 cycles after RT. Purpose: Improve survival after RT in IDH‑mutant, 1p/19q non‑codeleted anaplastic glioma. Mechanism: Alkylates DNA (O6‑guanine), causing tumor cell death; benefit relates to IDH status and may be influenced by MGMT promoter methylation. Side‑effects: Low blood counts, nausea, fatigue; needs PJP prophylaxis when combined with RT. [8–11,16,17,20]
2. PCV (Procarbazine, Lomustine/CCNU, Vincristine)
   Class: Multi‑agent alkylating + vinca regimen. Dose/Time: Typical cycle: Lomustine 110 mg/m² Day 1; Procarbazine 60 mg/m² Days 8–21; Vincristine 1.4 mg/m² (max 2 mg) IV Days 8 & 29, repeated every 6–8 weeks for up to 6 cycles (doses adjusted). Purpose: Alternative to TMZ after RT in some IDH‑mutant grade 3 cases. Mechanism: Multi‑mechanistic DNA damage and mitotic arrest. Side‑effects: Myelosuppression, neuropathy, nausea; careful blood count monitoring required. [5,8,11,18,19]
3. Dexamethasone
   Class: Corticosteroid. Dose/Time: The lowest effective dose for the shortest time (often 2–16 mg/day split; taper ASAP). Purpose: Reduce brain swelling and headache/neurologic symptoms. Mechanism: Anti‑inflammatory effect reduces blood–brain barrier leak and edema. Side‑effects: High sugar, infection risk, mood changes, muscle weakness; higher cumulative doses are linked to worse survival—another reason to taper quickly. [32–34]
4. Levetiracetam
   Class: Antiseizure (SV2A modulator). Dose/Time: Often 500–1,500 mg twice daily, adjusted. Purpose: Treat seizures; many providers prefer it after a first seizure due to efficacy and fewer interactions. Mechanism: Modulates synaptic vesicle protein SV2A to dampen neuronal hyper‑excitability. Side‑effects: Somnolence, mood changes; generally well‑tolerated. [14–16]
5. Ondansetron (or similar 5‑HT3 antiemetic)
   Class: Antiemetic. Dose/Time: 8 mg before chemotherapy and 8 mg q8–12h as needed. Purpose: Prevent nausea/vomiting from TMZ or PCV. Mechanism: Blocks serotonin 5‑HT3 receptors in gut/brain. Side‑effects: Constipation, headache, QT prolongation risk. [11]
6. Trimethoprim‑sulfamethoxazole (TMP‑SMX) for PJP prophylaxis
   Class: Antibiotic prophylaxis. Dose/Time: Commonly DS tablet three times weekly or daily during concurrent chemoradiation and until blood counts recover. Purpose: Prevent Pneumocystis jirovecii pneumonia with TMZ+RT. Mechanism: Folate pathway inhibition suppresses Pneumocystis replication. Side‑effects: Rash, cytopenias; alternatives exist if sulfa allergy. [20,21]
7. Proton pump inhibitor (e.g., Omeprazole)
   Class: Acid suppression. Dose/Time: 20–40 mg daily if on steroids or NSAIDs and at GI‑bleed risk. Purpose: Prevent gastritis/ulcer while on dexamethasone. Mechanism: Inhibits gastric acid pump. Side‑effects: Headache, infection risk with long‑term use. [12]
8. Enoxaparin (LMWH) for VTE treatment/prophylaxis when indicated
   Class: Anticoagulant. Dose/Time: Typical 1 mg/kg twice daily (treatment) if safe; timing individualized due to intracranial bleeding risk. Purpose: Treat or prevent blood clots, which are common in brain tumors. Mechanism: Potentiates antithrombin to inhibit factor Xa. Side‑effects: Bleeding; decision is case‑by‑case. [31]
9. Bevacizumab (selected situations)
   Class: Anti‑VEGF monoclonal antibody. Dose/Time: 10 mg/kg IV every 2 weeks (varies). Purpose: Considered for radiation necrosis or symptomatic, recurrent high‑grade glioma to reduce edema and steroid needs; not curative. Mechanism: Reduces abnormal tumor blood vessels and vasogenic edema. Side‑effects: Hypertension, bleeding, clots, wound‑healing delay. [36,37]
10. Hematopoietic growth factor (filgrastim/pegfilgrastim)
    Class: G‑CSF. Dose/Time: Per protocol after PCV/TMZ if neutropenia risk is high. Purpose: Shorten neutropenia and reduce infection. Mechanism: Stimulates neutrophil production. Side‑effects: Bone pain, rare splenic issues. [11,18]
11. Acetazolamide or mannitol (peri‑operative/acute ICP management)
    Class: Carbonic anhydrase inhibitor/osmotic diuretic. Dose/Time: Short courses when clinically indicated. Purpose: Temporize intracranial pressure elevations. Mechanism: Reduce CSF production (acetazolamide) or draw fluid from brain (mannitol). Side‑effects: Electrolyte issues, dehydration—specialist use only. [12]
12. Lacosamide (adjunctive antiseizure)
    Class: Sodium‑channel modulator. Dose/Time: Often 100–200 mg twice daily if seizures persist. Purpose: Add‑on control with favorable interaction profile. Mechanism: Slow inactivation of voltage‑gated sodium channels. Side‑effects: Dizziness, PR‑interval prolongation. [14,15]
13. Docusate/senna (bowel regimen)
    Class: Stool softener + stimulant laxative. Dose/Time: Daily while on opioids/antiemetics. Purpose: Prevent constipation. Mechanism: Improves stool water and motility. Side‑effects: Cramping. [12]
14. Metformin for steroid‑induced hyperglycemia (in appropriate patients)
    Class: Biguanide. Dose/Time: Titrated with endocrinology input. Purpose: Control glucose during dexamethasone therapy. Mechanism: Lowers hepatic glucose output and improves insulin sensitivity. Side‑effects: GI upset; avoid with renal failure. [26,27]
15. Mirtazapine (sleep/appetite/mood)
    Class: Antidepressant. Dose/Time: 7.5–15 mg at night. Purpose: Help sleep, appetite, and mood in selected patients. Mechanism: Noradrenergic/serotonergic modulation; antihistaminic at low doses. Side‑effects: Sedation, weight gain. [12]
16. Dronabinol (selected cases)
    Class: Cannabinoid. Dose/Time: 2.5–5 mg, individualized. Purpose: Appetite and nausea support where legal and appropriate. Mechanism: CB1 receptor agonism modulates nausea and appetite. Side‑effects: Drowsiness, dysphoria. (Discuss legality and interactions.) [12]
17. Topical/IV antiemetics (e.g., aprepitant or olanzapine in CINV protocols)
    Class: NK1 antagonist / atypical antipsychotic. Dose/Time: Per chemo‑induced nausea/vomiting guidelines. Purpose: Prevent delayed CINV with PCV. Mechanism: NK1 blockade (aprepitant) and multi‑receptor antiemesis (olanzapine). Side‑effects: Fatigue, constipation; QT/interaction checks needed. [11]
18. Prophylactic antivirals/antifungals when profoundly immunosuppressed
    Class: Varies (acyclovir, fluconazole). Dose/Time: Based on risk and counts. Purpose: Prevent opportunistic infections during intense chemotherapy. Mechanism: Suppress viral/fungal replication. Side‑effects: Renal/hepatic effects, interactions. [20]
19. Pain control (acetaminophen; cautious NSAID use)
    Class: Analgesics. Dose/Time: Per need; avoid NSAIDs around surgery/bleeding risk. Purpose: Headache and post‑op pain control. Mechanism: Central COX modulation or prostaglandin inhibition. Side‑effects: Liver toxicity (acetaminophen), GI/bleeding with NSAIDs. [12]
20. Vaccinations (e.g., influenza) coordinated with oncology
    Class: Immunization. Time: Ideally when counts are adequate and not within days of chemo. Purpose: Reduce infection risk leading to treatment delays. Mechanism: Adaptive immune priming. Side‑effects: Local reaction; avoid live vaccines if immunosuppressed. [12]

⚠️ Drug doses are typical starting points from guidelines/reviews; your oncologist tailors them to labs, side‑effects, and comorbidities. Always follow your care team’s instructions. [11,17]

Dietary molecular supplements

1. Vitamin D — Low levels are common in cancer. Adequate 800–2,000 IU/day may support bone, muscle, and mood, especially with steroid use. Mechanism: nuclear receptor effects on calcium and immune function. Evidence supports replacement when deficient; not a tumor treatment. [24,34]
2. Omega‑3 fatty acids (EPA/DHA) — Dose 1–2 g/day of combined EPA/DHA may help appetite, inflammation, and weight maintenance. Mechanism: anti‑inflammatory eicosanoid shift and membrane effects. Evidence in mixed‑cancer populations suggests benefit for cachexia and QoL. [24]
3. Ginger extract — 500–1,000 mg/day may lessen nausea with chemo. Mechanism: 5‑HT3 and substance‑P modulation in gut. Generally safe; watch interactions. [11]
4. Probiotics — 10–20 billion CFU/day may improve bowel regularity during antibiotics/antiemetics. Mechanism: microbiome support. Avoid in severe neutropenia. [24]
5. Magnesium (if low) — 200–400 mg/day may reduce cramps/headache; corrects deficits from diuretics. Mechanism: neuronal excitability and vascular tone. [12]
6. Melatonin — 3–10 mg nightly may improve sleep and reduce steroid‑related insomnia; antitumor effects remain investigational. Mechanism: circadian and antioxidant signaling. [12]
7. B‑complex vitamins (if deficient) — Replace per labs to support energy/neuropathy prevention. Mechanism: co‑factor roles in nerve and RBC function. [12]
8. Fiber (psyllium, soluble fiber) — 5–10 g/day to help constipation from antiemetics/opioids. Mechanism: stool water retention and microbiome metabolites. [12]
9. Protein supplements (whey/plant) — 20–30 g/day supplement to meet protein targets during treatment. Mechanism: muscle repair and immune support. [24]
10. Curcumin (experimental) — Up to 1–2 g/day standardized extract has anti‑inflammatory/epigenetic signals in preclinical glioma models; human evidence is limited—use only with oncology approval due to interactions. [22]

ASCO cautions that evidence for most diet/supplement strategies during active cancer treatment is limited; avoid high‑dose or unverified products unless your team recommends them. [22,23]

Investigational “immunity‑/regenerative‑/stem‑cell–related

1. PD‑1 inhibitors (nivolumab/pembrolizumab) — Limited activity in most gliomas, but considered in trials or in mismatch‑repair–deficient/hypermutated cases. Mechanism: T‑cell activation by checkpoint blockade. [22]
2. IDH inhibitors (ivosidenib, vorasidenib) — Designed for IDH‑mutant gliomas; vorasidenib improved progression‑free survival in grade 2 and is under further study across grades. Mechanism: Blocks D‑2HG production to reverse epigenetic blockade. [31,32]
3. Vaccine approaches (peptide/DC vaccines) — Aim to train the immune system against tumor antigens (e.g., IDH neoantigens). Still investigational. [22]
4. Oncolytic viruses — Engineered viruses to infect and kill tumor cells and prime immunity; early‑phase studies only. [22]
5. CAR‑T / adoptive T‑cells — T‑cells engineered against glioma targets (e.g., EGFRvIII); significant hurdles remain. [22]
6. Neural stem‑cell–delivered therapeutics (experimental) — Cells used as carriers of drugs/viruses toward infiltrating tumor front; research stage. [22]

Discuss eligibility with your center; availability varies and risks can be significant. [22,31]

Surgeries

1. Stereotactic biopsy — A small burr hole is made; MRI guidance directs a needle to sample tumor for pathology and molecular tests when resection is unsafe. Why: Secure diagnosis to guide therapy. [21]
2. Awake craniotomy with language/motor mapping — Tumor near speech or motor cortex is removed while you perform tasks so surgeons can map and protect critical areas. Why: Maximizes tumor removal while preserving function. [29,30]
3. Standard craniotomy (asleep) with neuronavigation — Larger resections away from eloquent cortex under general anesthesia. Why: Debulk tumor to improve symptoms and response to adjuvant therapy. [28]
4. Re‑resection at recurrence (selected) — Repeat surgery if tumor is focal and accessible. Why: Lower mass effect, obtain updated molecular profile, and open options for trials. [28]
5. CSF diversion (ventriculoperitoneal shunt or endoscopic third ventriculostomy) — Performed if hydrocephalus develops. Why: Relieve pressure and headaches from blocked CSF flow. [12]

Preventions

1. Seizure plan and medication adherence to prevent injuries. [14–16]
2. Early steroid taper to the lowest dose to reduce diabetes, infections, and muscle loss. [32–34]
3. PJP prophylaxis during TMZ+RT. [20,21]
4. VTE prevention after surgery and during reduced mobility. [25,31]
5. Vaccinations (influenza, COVID‑19 per policy) when counts allow. [12]
6. Exercise program to reduce fatigue and deconditioning. [22,23]
7. Nutrition and glucose monitoring while on steroids. [26,27,34]
8. Fall prevention and home safety (grab bars, lighting). [12]
9. Skin care & BP monitoring on bevacizumab. [36,37]
10. Regular follow‑up MRI on schedule to catch recurrence early. [5,17,18]

When to see doctors urgently

Call or go to emergency care for new or worsening neurologic symptoms (weakness, speech trouble, seizures, severe headache, confusion), fever or shortness of breath, severe vomiting preventing fluids, signs of blood clots (leg swelling/pain, chest pain), or new high blood sugars on steroids. Rapid evaluation helps treat swelling, bleeding, seizures, infection, or clotting before complications occur. [12,31,33]

What to eat” and “what to avoid

Eat:

1. Balanced meals with lean protein (fish, eggs, legumes) each meal to protect muscle.
2. Whole grains, fruits, and vegetables for fiber, vitamins, and bowels.
3. Healthy fats (olive oil, nuts, omega‑3 fish) for calories and inflammation balance.
4. Calcium/vitamin D sources (dairy or fortified alternatives) if on steroids.
5. Plenty of fluids, small frequent meals on treatment days.

Avoid/limit:

1. Very salty foods (steroids cause fluid retention).
2. Sugary drinks (worsen steroid‑induced hyperglycemia).
3. Alcohol (seizure risk and drug interactions).
4. Raw/unpasteurized items when white counts are low; follow your team’s neutropenia precautions.
5. High‑dose supplements or herbals not cleared by oncology (interactions). Evidence does not support restrictive “neutropenic diets” in most patients. [22–24,26,27,34]

FAQs

1. Is “grade III” the same as “anaplastic astrocytoma”?
   Mostly yes, but the modern name is astrocytoma, IDH‑mutant, grade 3. Molecular tests decide the final label and plan. [1,2,17]
2. What treatment improves survival the most?
   For IDH‑mutant grade 3, radiation followed by 12 cycles of adjuvant temozolomide is the regimen with the strongest survival data (CATNON). [8,17]
3. Do I still need chemotherapy if surgery removed everything?
   Yes, because microscopic cells remain; RT and adjuvant TMZ lower the risk of regrowth. [5,8,17]
4. Is temozolomide during radiation necessary?
   CATNON found adjuvant TMZ drove the survival benefit in IDH‑mutant; the concurrent part didn’t add clear benefit in this setting. Your team individualizes care. [8–11,16,17]
5. What about PCV instead of TMZ?
   Some centers use PCV after RT; it may have more side‑effects. No modern trial directly proves TMZ vs PCV superiority in grade 3 IDH‑mutant astrocytoma. [5,11,18]
6. How often will I get MRI scans?
   Commonly every 3–4 months at first, then spaced out if stable. Schedules vary. [5,17]
7. Can exercise help?
   Yes—exercise reduces fatigue and other side‑effects and improves quality of life during cancer treatment. Start gradually with guidance. [22,23]
8. Are steroids safe long term?
   They help swelling but cause major side‑effects; aim for the smallest dose for the shortest time and taper when possible. [32–34]
9. Do I need seizure medicine if I never had a seizure?
   Routine preventive AEDs are not universally recommended; many clinicians start levetiracetam after a first seizure, not before. [14,33]
10. Is bevacizumab a cure?
    No. It can shrink edema and help symptoms (including radiation necrosis) but has not proven to prolong survival in this disease. [36,37]
11. Should I follow a ketogenic diet?
    Some research explores metabolic diets in glioma, but strong proof is lacking; discuss with your team to avoid weight loss or interactions. [24]
12. Are IDH inhibitors available?
    They are under study; one agent improved PFS in grade 2 disease. Trials are expanding for higher grades. [31,32]
13. Will I lose my job or driving license?
    This depends on symptoms, seizures, and local rules; your team can advise and help with workplace or driving evaluations. [14,33]
14. What is my outlook?
    Outcomes vary by age, extent of resection, and tumor biology (IDH, MGMT). Modern combined therapy has improved survival compared with older eras. [17,28]
15. Should I join a clinical trial?
    If available, yes—trials help you access new options and move the field forward. [18,22]

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.